Back to today’s briefing

Story perspectives

Revolutionary Gene Therapies Slash Cholesterol Levels by 69%

6/10/2025

50 3

Summary

Story summary

VERVE-102 and YOLT-101 are groundbreaking treatments for heterozygous familial hypercholesterolemia, focusing on the PCSK9 gene to significantly lower LDL cholesterol levels. In a small trial, VERVE-102 achieved an impressive 69% reduction, while YOLT-101 has gained FDA approval for its cutting-edge gene editing technique. Together, they promise a revolutionary one-time solution for those battling high cholesterol.

1 of 1

Story summary

VERVE-102 and YOLT-101 are groundbreaking treatments for heterozygous familial hypercholesterolemia, focusing on the PCSK9 gene to significantly lower LDL cholesterol levels. In a small trial, VERVE-102 achieved an impressive 69% reduction, while YOLT-101 has gained FDA approval for its cutting-edge gene editing technique. Together, they promise a revolutionary one-time solution for those battling high cholesterol.